SCHEDULE: ATAI Life Sciences Reduces COMPASS Pathways Stake
Beneficial Ownership Amendment
ATAI Life Sciences N.V. reported a reduction in its beneficial ownership of COMPASS Pathways plc to 6.0% through recent open market sales.
Summary
- ATAI Life Sciences N.V. now beneficially owns 5,785,774 Ordinary Shares of COMPASS Pathways plc, representing approximately 6.0% of the outstanding shares.
- This is a decrease from previous holdings, as ATAI N.V. sold a total of 220,000 American Depositary Shares (ADSs) between October 22, 2025, and October 28, 2025.
- The sales were conducted at prices ranging from $6.2949 to $6.5801 per share.
- ATAI Life Sciences AG ceased to be a beneficial owner in April 2025 due to a corporate reorganization, with ATAI Life Sciences N.V. becoming the direct holder.
- The total outstanding shares of COMPASS Pathways plc were 95,941,264 as of July 28, 2025.
Sentiment
Score: 4
Explanation: The sale of a significant number of shares by a major institutional investor like ATAI Life Sciences N.V. is generally viewed negatively by the market, as it can signal a lack of confidence or a strategic shift. While the corporate reorganization is neutral, the divestment aspect is a negative signal.
Negatives
- ATAI Life Sciences N.V., a significant holder, sold 220,000 ADSs of COMPASS Pathways plc in open market transactions.
- The reduction in stake from a major investor could signal a lack of confidence or a strategic shift away from the investment.
Future Outlook
No forward-looking statements or guidance provided in this filing.
Industry Context
This filing primarily concerns a change in a major shareholder's stake and internal corporate restructuring of the shareholder. It does not provide direct insights into broader industry trends for COMPASS Pathways plc or the psychedelic-assisted therapy sector, other than potentially reflecting a strategic decision by ATAI Life Sciences regarding its investment portfolio.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Shareholder Structure | ATAI Life Sciences AG converted into a German GmbH in April 2025, and ATAI Life Sciences N.V. became the direct beneficial owner of the shares previously held by ATAI Life Sciences AG. | April 2025 | This is an internal corporate reorganization of the reporting person (ATAI), not a change in COMPASS Pathways plc's corporate governance. It clarifies the direct holder of the shares. |
Stakeholder Impact
- Shareholders: Existing shareholders may view the reduction in stake by a major investor negatively, potentially leading to downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 2021-05-24 | Original Schedule 13D filed with the SEC. |
| 2025-04 | Corporate reorganization where ATAI Life Sciences AG converted to a German GmbH and ceased beneficial ownership, with ATAI Life Sciences N.V. becoming the direct holder. |
| 2025-07-28 | Date for which 95,941,264 Ordinary Shares outstanding were disclosed in the Issuer's Form 10-Q. |
| 2025-07-31 | Date Issuer's Quarterly Report on Form 10-Q was filed. |
| 2025-10-22 | ATAI N.V. sold 20,000 ADSs at $6.3194 per share. |
| 2025-10-23 | ATAI N.V. sold 20,000 ADSs at $6.2949 per share. |
| 2025-10-24 | ATAI N.V. sold 60,000 ADSs at $6.3714 per share. |
| 2025-10-27 | Date of event requiring filing; ATAI N.V. sold 60,000 ADSs at $6.5801 per share. |
| 2025-10-28 | ATAI N.V. sold 60,000 ADSs at $6.4946 per share. |
| 2025-10-29 | Date of signing of this Schedule 13D Amendment No. 5. |
Recommendation
holdWhile the sale of shares by a major investor like ATAI Life Sciences N.V. is a negative signal, the filing itself does not provide fundamental operational or financial news about COMPASS Pathways plc. The reduction in stake could be due to various reasons, including portfolio rebalancing by ATAI. Without further information on COMPASS Pathways' underlying business performance or strategic direction, a 'hold' recommendation is appropriate, advising investors to monitor future developments and the company's next financial reports before making a definitive buy or sell decision.
Keywords
COMPASS Pathways, ATAI Life Sciences, CMPS, Schedule 13D, Share Sales, Beneficial Ownership, SEC Filing, Biotechnology, Psychedelics, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.